Abstract
Inactivation of the P16 (INK4A)/retinoblastoma (RB) or TP53 biochemical pathway is frequent event in most human cancers. Recent evidence has shown that P14ARF binds to MDM2 leading to an increased availability of wild type TP53 protein. Functional studies also support a putative tumor suppressor gene function for p14ARF suggesting that p14ARF or p53 inactivation may be functionally equivalent in tumorigenesis. To study the relative contribution of each pathway in tumorigenesis, we analysed and compared alterations of the p16, p14ARF and p53 genes in 38 primary non-small cell lung cancers (NSCLCs) (19 adenocarcinomas and 19 squamous carcinoma). The p16 tumor suppressor gene was inactivated in 22 of 38 (58%) tumors. Twelve of these samples (31%) had homozygous deletions by microsatellite analysis; eight of them (21%) had p16 promoter hypermethylation detected by Methylation Specific PCR (MSP) and the remaining two (5%) harbored a point mutation in exon 2 by sequence analysis. The absence of P16 protein in every case was confirmed by immunohistochemistry. Fourteen of the 22 tumors with p16 inactivation also inactivated the p14ARF gene (12 with homozygous deletions extending into INK4a/ARF and two with exon 2 mutations). Mutations of p53 were found in 18 (47%) of the tumors and nine of them (50%) harbored p14ARF inactivation. Thus, an inverse correlation was not found between p14ARF and p53 genetic alterations (P=0.18; Fisher Exact Test). Our data confirm that the p16 gene is frequently inactivated in NSCLC. Assuming that 9p deletion occurs first, the common occurrence of p53 and p14ARF alterations suggests that p14ARF inactivation is not functionally equivalent to abrogation of the TP53 pathway by p53 mutation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- AD:
-
adenocarcinoma
- HD:
-
homozygous deletion
- IHC:
-
immunohistochemistry
- LOH:
-
loss of heterozygosity
- NSCLC:
-
non small cell lung cancer
- SCC:
-
squamous cell carcinoma
References
Arhrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J and Sidransky D. . 1999 Proc. Natl. Acad. Sci. USA 96: 7382–7387.
Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE and Sidransky D. . 1994 Science 265: 415–417.
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Bucker A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova SG, Isaacs W, Koch W, Schwab D and Sidransky D. . 1995 Nature Genet. 11: 210–212.
Chin L, Pomerantz J and DePinho RA. . 1998 Trends Biochem. Sci. 23: 291–296.
Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larse CJ and Brambilla E. . 1998 Cancer Res. 58: 3926–3931.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB. . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826.
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosreld G and Sherr CJ. . 1997 Cell 91: 649–654.
Kinoshita I, Dosaka-Akita H, Mishina T, Akie K, Nishi M, Hiroumi H, Hommura F and Kawakami Y. . 1996 Cancer Res. 56: 5557–5562.
Ko LJ and Prives C. . 1996 Genes Dev. 10: 1054–1072.
Kratzke R, Shimizu E and Kaye F. . 1992 Cancer Treat. Res. 63: 61–85.
Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE and Niehans GA. . 1996 Cancer Res. 56: 3415–3420.
Larsen CJ. . 1996 Oncogene 16: 2041–2044.
Ling L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N and Hogg D. . 1999 Nature Genet. 21: 128–132.
Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Barrett JR and Sidransky D. . 1995 Cancer Res. 55: 2995–2997.
Markl IDC and Jones P. . 1998 Cancer Res. 55: 5348–5353.
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D. . 1995 Nature Med. 1: 686–692.
Mitsudomi T and Takahashi T. . 1996 Japan. J. Cancer Chem. 23: 990–996.
Munro J, Scott FJ, Vousden KH, Peters G and Parkinson EK. . 1999 Cancer Res. 59: 2516–2521.
Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J and Sidransky D. . 1996 Cancer Res. 56: 3630–3633.
Robertson KD and Jones PA. . 1998 Mol. Cell Biol. 18: 6457–6473.
Sidransky D. . 1996 Curr. Biol. 6: 523–525.
Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, et al. 1991 Science 252: 706–709.
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G and Kamb A. . 1995 Cancer Res. 5: 2988–2994.
Van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W and Sidransky D. . 1994 Cancer Res. 54: 1156–1158.
Acknowledgements
Supported by Lung Spore grant CA 58184 and an award to J Jen from the James Valvano Foundation. M Sanchez-Cespedes is a recipient of a Spanish Ministerio de Educacion y Cultura Award.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sanchez-Cespedes, M., Reed, A., Buta, M. et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 18, 5843–5849 (1999). https://doi.org/10.1038/sj.onc.1203003
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203003
Keywords
This article is cited by
-
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice
Oncogene (2022)
-
Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!
Molecular and Cellular Biochemistry (2021)
-
Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study
World Journal of Surgical Oncology (2015)
-
ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma
Oncogene (2014)
-
Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer
Clinical and Translational Oncology (2014)